ZURICH, Oct. 23, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (Nasdaq: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system ("CNS") disorders, and Kadimastem Ltd. (TASE: KDST) ("Kadimastem"), an advanced...
Hence then, the article about nls and kadimastem announce receipt of nasdaq approval merger expected to close on october 30 2025 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025 )
Also on site :
- Doritos Is Finally Bringing This Cult-Favorite International Flavor to the U.S.
- The 12 Best Matcha Powders, According to a Daily Drinker Who's Tried Them All
- 2 injured, suburban Walmart closed after fire damages store